Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSF1 | Q00613 | 6/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bgp-15 SCHEMBL12998977 | 1.00 | HSF1 (0.46) | HSF1CYP2D6TSHRHIF1AATM | |
| Bgp-15 SCHEMBL29354224 | 1.00 | HSF1 (0.46) | HSF1CYP2D6TSHRHIF1AATM | |
| Bgp-15 SCHEMBL29687972 | 0.99 | HSF1 (0.45) | HSF1CYP2D6TSHRHIF1AATM | |
| Bgp-15 SCHEMBL3067998 | 0.99 | HSF1 (0.45) | HSF1CYP2D6TSHRHIF1AATM | |
| Bgp-15 SCHEMBL31396023 | 0.99 | HSF1 (0.45) | HSF1CYP2D6TSHRHIF1AATM | |
| Bgp-15 SCHEMBL29857974 | 0.99 | HSF1 (0.45) | HSF1CYP2D6TSHRHIF1AATM | |
| Bgp-15 SCHEMBL11320758 | 0.94 | HSF1 (0.44) | HSF1CYP2D6TSHRHIF1ALMNA | |
| Hydrochloric Acid SCHEMBL3066262 | 0.87 | LMNA (0.42) | CYP2D6LMNAALDH1A1CYP2C19DRD4 | |
| Bimoclomol SCHEMBL19463989 | 0.86 | HSF1 (0.56) | HSF1CYP2D6TSHRHIF1AATM | |
| Bimoclomol SCHEMBL19463987 | 0.86 | HSF1 (0.56) | HSF1CYP2D6TSHRHIF1AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630105-A1 | HEAT SHOCK PROTEIN INDUCERS AND FRONTOTEMPORAL DISORDERS | Orphazyme A/S (DK) | 2020-04-08 | — | — | EP | claimed |
| US-20200085812-A1 | HEAT SHOCK PROTEIN INDUCERS AND FRONTOTEMPORAL DISORDERS | KEMPHARM, INC. | 2020-03-19 | — | — | US | claimed |
| US-20190201389-A1 | HEAT SHOCK PROTEINS AND CHOLESTEROL HOMEOSTASIS | Zevra Denmark A/S (DK) | 2019-07-04 | — | — | US | claimed |
| EP-3442530-A1 | HEAT SHOCK PROTEINS AND CHOLESTEROL HOMEOSTASIS | Orphazyme A/S (DK) | 2019-02-20 | — | — | EP | claimed |
| WO-2018215597-A1 | HEAT SHOCK PROTEIN INDUCERS AND FRONTOTEMPORAL DISORDERS | ORPHAZYME A/S (DK) | 2018-11-29 | — | — | WO | claimed |
| WO-2017178029-A1 | HEAT SHOCK PROTEINS AND CHOLESTEROL HOMEOSTASIS | ORPHAZYME APS (DK) | 2017-10-19 | — | — | WO | claimed |
| EP-2089032-B1 | A PHARMACEUTICAL COMPOSITION HAVING ANTIPSYCHOTIC, ANTIDEPRESSANT OR ANTIEPILEPTIC ACTIVITY WITH REDUCED SIDE EFFECT | N GENE RES LAB INC (US) | 2010-12-15 | — | — | EP | claimed |
| EP-2089031-B1 | REDUCTION OF OVERWEIGHT OR OBESITY | N GENE RES LAB INC (US) | 2010-11-24 | — | — | EP | claimed |
| EP-0852495-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING HYDROXIMIC ACID DERIVATIVES | N GENE RES LAB INC (US) | 2006-03-29 | — | — | EP | claimed |
| US-4187220-A | New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA R.T. (HU) | 1980-02-05 | — | — | US | claimed |
| US-20210186949-A1 | HEAT SHOCK PROTEINS AND CHOLESTEROL HOMEOSTASIS | KEMPHARM, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210164997-A1 | HSP70 PROTEIN LEVELS IN PBMC SAMPLES AS BIOMARKER FOR DISEASE | Zevra Denmark A/S (DK) | 2021-06-03 | — | — | US | disclosed |
| EP-3803406-A1 | HSP70 PROTEIN LEVELS IN PBMC SAMPLES AS BIOMARKER FOR DISEASE | Orphazyme A/S (DK) | 2021-04-14 | — | — | EP | disclosed |
| US-10898476-B2 | Heat shock proteins and cholesterol homeostasis | ORPHAZYME A/S (DK) | 2021-01-26 | — | — | US | disclosed |
| EP-3630105-A1 | HEAT SHOCK PROTEIN INDUCERS AND FRONTOTEMPORAL DISORDERS | Orphazyme A/S (DK) | 2020-04-08 | — | — | EP | disclosed |
| WO-2000035914-A1 | OPTICALLY ACTIVE PYRIDYL-4H-1,2,4-OXADIAZINE DERIVATIVE AND ITS USE IN THE TREATMENT OF VASCULAR DISEASES | Biorex Kutató és Fejleszto Rt. (HU) | 2000-06-22 | — | — | WO | disclosed |
| EP-0966283-A2 | PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING ILLNESSES CONNECTED WITH THE MALFUNCTION OF VASCULAR ENDOTHELIAL CELLS | BIOREX RT. (HU) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998006400-A2 | PHARMACEUTICAL PRODUCTS FOR CURING AND PREVENTING ILLNESSES CONNECTED WITH THE MALFUNCTION OF VASCULAR ENDOTHELIAL CELLS | BIOREX KUTATÓ ÉS FEJLESZTO^' RT. (HU) | 1998-02-19 | — | — | WO | disclosed |
| EP-0801649-A2 | HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF | BIOREX KUTATO ES FEJLESZTÖ RT. (HU) | 1997-10-22 | — | — | EP | disclosed |
| WO-1997016439-A1 | HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE MOLECULAR CHAPERON PRODUCTION AND THE PREPARATION THEREOF | Biorex Kutató és Fejlesztó Rt. (HU) | 1997-05-09 | — | — | WO | disclosed |